Novartis Guidance Points to Slow Second Half

Dow Jones

Jul 21

0744 GMT - Novartis reaffirmed its full-year guidance after second-quarter results beat expectations, which implies a slow second half, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The Swiss drugmaker expects this year's sales to grow by a low-single-digit percentage, and core operating profit to decline by a similar amount, when excluding currency changes. This follows declines of 2% for sales and 7% for core operating profit in the first half, the analysts say. Among the company's key products, anti-inflammatory drug Cosentyx, multiple-sclerosis treatment Kesimpta and leukemia medicine Scemblix all beat expectations, the analysts say. Breast-cancer medicine Kisqali and prostate-cancer therapy missed forecasts, they add. Shares rise 1.9%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 21, 2026 03:44 ET (07:44 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653114222"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653114222\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653114222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653114222","market":"hk","top_or_hot":-1,"title":"Novartis Guidance Points to Slow Second Half","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0744 GMT - Novartis reaffirmed its full-year guidance after second-quarter results beat expectations, which implies a slow second half, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The Swiss drugmaker expects this year's sales to grow by a low-single-digit percentage, and core operating profit to decline by a similar amount, when excluding currency changes. This follows declines of 2% for sales and 7% for core operating profit in the first half, the analysts say. Among the company's key products, anti-inflammatory drug Cosentyx, multiple-sclerosis treatment Kesimpta and leukemia medicine Scemblix all beat expectations, the analysts say. Breast-cancer medicine Kisqali and prostate-cancer therapy missed forecasts, they add. Shares rise 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 03:44 ET (07:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Guidance Points to Slow Second Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Guidance Points to Slow Second Half\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-21 15:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0744 GMT - Novartis reaffirmed its full-year guidance after second-quarter results beat expectations, which implies a slow second half, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The Swiss drugmaker expects this year's sales to grow by a low-single-digit percentage, and core operating profit to decline by a similar amount, when excluding currency changes. This follows declines of 2% for sales and 7% for core operating profit in the first half, the analysts say. Among the company's key products, anti-inflammatory drug Cosentyx, multiple-sclerosis treatment Kesimpta and leukemia medicine Scemblix all beat expectations, the analysts say. Breast-cancer medicine Kisqali and prostate-cancer therapy missed forecasts, they add. Shares rise 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 03:44 ET (07:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653114222","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653114222","pubTimestamp":1784619840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0744 GMT - Novartis reaffirmed its full-year guidance after second-quarter results beat expectations, which implies a slow second half, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The Swiss drugmaker expects this year's sales to grow by a low-single-digit percentage, and core operating profit to decline by a similar amount, when excluding currency changes. This follows declines of 2% for sales and 7% for core operating profit in the first half, the analysts say. Among the company's key products, anti-inflammatory drug Cosentyx, multiple-sclerosis treatment Kesimpta and leukemia medicine Scemblix all beat expectations, the analysts say. Breast-cancer medicine Kisqali and prostate-cancer therapy missed forecasts, they add. Shares rise 1.9%.  Dow Jones NewswiresJuly 21, 2026 03:44 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4007":"制药","NVS":"诺华","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","MEDX":"HORIZON KINETICS MEDICAL ETF","BK4532":"文艺复兴科技持仓","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","PCOM":"Points International","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4122":"互联网与直销零售","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4578":"CAR-T","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","PPH":"VanEck Pharmaceutical ETF","BK4588":"碎股"},"translate_title":"诺华指引指出下半年放缓","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDX":0.6,"PCOM":1.5,"NVS":0.9,"PPH":0.6},"content_text":"0744 GMT - Novartis reaffirmed its full-year guidance after second-quarter results beat expectations, which implies a slow second half, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The Swiss drugmaker expects this year's sales to grow by a low-single-digit percentage, and core operating profit to decline by a similar amount, when excluding currency changes. This follows declines of 2% for sales and 7% for core operating profit in the first half, the analysts say. Among the company's key products, anti-inflammatory drug Cosentyx, multiple-sclerosis treatment Kesimpta and leukemia medicine Scemblix all beat expectations, the analysts say. Breast-cancer medicine Kisqali and prostate-cancer therapy missed forecasts, they add. Shares rise 1.9%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 21, 2026 03:44 ET (07:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}